Therapeutics News and Research

RSS

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology.

11 Jun 2014

Wolters Kluwer announces feature-rich online platform for LWW Health Library

Wolters Kluwer Health, a leading global provider of information and point-of-care solutions for healthcare and medical education, today announced a new, feature-rich online platform developed for the LWW Health Library, a portal to a diverse collection of Lippincott basic and clinical science content used by medical and pharmacy schools.

10 Jun 2014

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 in development for the treatment of complement-mediated diseases.

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Penn researchers awarded $10 million grant to study adverse health effects, remediation of asbestos

Researchers at the Center of Excellence in Environmental Toxicology, Perelman School of Medicine at the University of Pennsylvania, have been awarded a $10 million grant from the National Institute for Environmental Health Sciences over the next four years to study asbestos exposure pathways that lead to mesothelioma, the bioremediation of this hazardous material, and mechanisms that lead to asbestos-related diseases.

10 Jun 2014

Seres Health closes $10 million Series B financing, signs research collaboration with Mayo Clinic

Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, announced today that it has closed its $10 million Series B financing that included existing investors Flagship Ventures and Enso Ventures, and included new investors, Mayo Clinic, Alexandria Venture Investments, and several private investors. The company has also entered into an exclusive research collaboration with the Mayo Clinic.

9 Jun 2014

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care.

9 Jun 2014

Merck enters into definitive agreement with Idenix

Merck, known as MSD outside the United States and Canada, and Idenix Pharmaceuticals, Inc., today announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash.

9 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

Advances in understanding of genetics of CAD lead to more therapeutic targets

Advances in the understanding of the genetics of coronary artery disease, or CAD, will revitalize the field and lead to more therapeutic targets for new medicines to combat this common disease, suggests a genetics expert from the Perelman School of Medicine at the University of Pennsylvania in a Perspective article in the new issue of Science Translational Medicine.

9 Jun 2014

Infants exposed to bacterial species in house dust are less likely to develop asthma

Infants exposed to a diverse range of bacterial species in house dust during the first year of life appear to be less likely to develop asthma in early childhood, according to a new study published online on June 6, 2014, in the Journal of Allergy and Clinical Immunology.

9 Jun 2014

Tech Collective invites applications and nominations for 2014 Rhode Island Bioscience Awards

Tech Collective, Rhode Island's Bioscience and Information Technology industry association, today announces the launch of its 2014 Rhode Island Bioscience Awards.

6 Jun 2014

TSRI scientists reveal molecular secret behind short, intense exercise

In the last few years, the benefits of short, intense workouts have been extolled by both researchers and exercise fans as something of a metabolic panacea capable of providing greater overall fitness, better blood sugar control and weight reduction-all of it in periods as short as seven minutes a few times a week.

6 Jun 2014

Researchers take step toward restoring natural, high-fidelity vision to blind people

In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object. Although more work remains, this is a step toward restoring natural, high-fidelity vision to blind people, the researchers say.

6 Jun 2014

University of Texas professor to receive Robert K. Chalmers Distinguished Pharmacy Educator Award

The American Association of Colleges of Pharmacy will honor Robert L. Talbert, Pharm.D., B.S., professor of pharmacotherapy in the College of Pharmacy at The University of Texas at Austin, for his excellence as a teacher, his outstanding achievements as an author and mentor, and his overall impact on pharmacy education and the profession.

6 Jun 2014

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies for acute, life-threatening neurological conditions, today announced that it has initiated patient enrollment in the second cohort of the NEWTON study, a multicenter, randomized, controlled, open-label, Phase 1/2 clinical trial of the company's lead product candidate, EG-1962.

5 Jun 2014

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics, a privately held company dedicated to bringing new anti-cancer therapies to market, announced today (June 4) that it has begun clinical trials of PFK-158, a small molecule therapeutic candidate that inactivates a novel cancer metabolism target never before examined in human clinical trials.

5 Jun 2014

$SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus$

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced preliminary data from its ongoing open-label Phase 1/2 clinical trial of SAGE-547, an allosteric modulator of GABAA receptors, in patients with super-refractory status epilepticus (SRSE).

5 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.

5 Jun 2014

Therapeutics News and Research

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Wolters Kluwer announces feature-rich online platform for LWW Health Library

Alnylam announces new pre-clinical results with DC for ALN-CC5 to treat complement-mediated diseases

Celsion signs definitive asset purchase agreement to acquire EGEN

Penn researchers awarded $10 million grant to study adverse health effects, remediation of asbestos

Seres Health closes $10 million Series B financing, signs research collaboration with Mayo Clinic

Celsus’ expert highlights serious side effects of topical corticosteroids

Merck enters into definitive agreement with Idenix

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Advances in understanding of genetics of CAD lead to more therapeutic targets

Infants exposed to bacterial species in house dust are less likely to develop asthma

Tech Collective invites applications and nominations for 2014 Rhode Island Bioscience Awards

TSRI scientists reveal molecular secret behind short, intense exercise

Researchers take step toward restoring natural, high-fidelity vision to blind people

University of Texas professor to receive Robert K. Chalmers Distinguished Pharmacy Educator Award

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Symphony continuous glucose monitoring system study selected for presentation at ADA scientific sessions

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News